COVID-19 in health-care workers in three hospitals in the south of the Netherlands: a cross-sectional study.

Autor:	Sikkema RS; Viroscience, Erasmus MC, Rotterdam, Netherlands. Electronic address: r.sikkema@erasmusmc.nl., Pas SD; Microvida Laboratory for Microbiology, Bravis Hospital, Roosendaal, Netherlands; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands., Nieuwenhuijse DF; Viroscience, Erasmus MC, Rotterdam, Netherlands., O'Toole Á; University of Edinburgh, Edinburgh, UK., Verweij J; Laboratory for Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands., van der Linden A; Viroscience, Erasmus MC, Rotterdam, Netherlands., Chestakova I; Viroscience, Erasmus MC, Rotterdam, Netherlands., Schapendonk C; Viroscience, Erasmus MC, Rotterdam, Netherlands., Pronk M; Viroscience, Erasmus MC, Rotterdam, Netherlands., Lexmond P; Viroscience, Erasmus MC, Rotterdam, Netherlands., Bestebroer T; Viroscience, Erasmus MC, Rotterdam, Netherlands., Overmars RJ; Viroscience, Erasmus MC, Rotterdam, Netherlands., van Nieuwkoop S; Viroscience, Erasmus MC, Rotterdam, Netherlands., van den Bijllaardt W; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands., Bentvelsen RG; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands; Department of Medical Microbiology, Leiden University Medical Center, Leiden, Netherlands., van Rijen MML; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands., Buiting AGM; Laboratory for Medical Microbiology and Immunology, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands; Department of Infection Control, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands., van Oudheusden AJG; Department of Infection Control, Elisabeth-TweeSteden Hospital, Tilburg, Netherlands., Diederen BM; Microvida Laboratory for Microbiology, Bravis Hospital, Roosendaal, Netherlands., Bergmans AMC; Microvida Laboratory for Microbiology, Bravis Hospital, Roosendaal, Netherlands., van der Eijk A; Viroscience, Erasmus MC, Rotterdam, Netherlands., Molenkamp R; Viroscience, Erasmus MC, Rotterdam, Netherlands., Rambaut A; University of Edinburgh, Edinburgh, UK., Timen A; Landelijke Coördinatie Infectieziektebestrijding, Rijksinstituut voor Volksgezondheid en Milieu, Bilthoven, Netherlands; VU University Amsterdam, Amsterdam, Netherlands., Kluytmans JAJW; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands; Department of Infection Control, Amphia Hospital, Breda, Netherlands., Oude Munnink BB; Viroscience, Erasmus MC, Rotterdam, Netherlands., Kluytmans van den Bergh MFQ; Julius Center for Health Sciences and Primary Care, University Medical Center Utrecht, Utrecht, Netherlands; Microvida Laboratory for Microbiology, Amphia Hospital, Breda, Netherlands; Department of Infection Control, Amphia Hospital, Breda, Netherlands., Koopmans MPG; Viroscience, Erasmus MC, Rotterdam, Netherlands.
Jazyk:	angličtina
Zdroj:	The Lancet. Infectious diseases [Lancet Infect Dis] 2020 Nov; Vol. 20 (11), pp. 1273-1280. Date of Electronic Publication: 2020 Jul 02.
DOI:	10.1016/S1473-3099(20)30527-2
Abstrakt:	Background: 10 days after the first reported case of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in the Netherlands (on Feb 27, 2020), 55 (4%) of 1497 health-care workers in nine hospitals located in the south of the Netherlands had tested positive for SARS-CoV-2 RNA. We aimed to gain insight in possible sources of infection in health-care workers. Methods: We did a cross-sectional study at three of the nine hospitals located in the south of the Netherlands. We screened health-care workers at the participating hospitals for SARS-CoV-2 infection, based on clinical symptoms (fever or mild respiratory symptoms) in the 10 days before screening. We obtained epidemiological data through structured interviews with health-care workers and combined this information with data from whole-genome sequencing of SARS-CoV-2 in clinical samples taken from health-care workers and patients. We did an in-depth analysis of sources and modes of transmission of SARS-CoV-2 in health-care workers and patients. Findings: Between March 2 and March 12, 2020, 1796 (15%) of 12 022 health-care workers were screened, of whom 96 (5%) tested positive for SARS-CoV-2. We obtained complete and near-complete genome sequences from 50 health-care workers and ten patients. Most sequences were grouped in three clusters, with two clusters showing local circulation within the region. The noted patterns were consistent with multiple introductions into the hospitals through community-acquired infections and local amplification in the community. Interpretation: Although direct transmission in the hospitals cannot be ruled out, our data do not support widespread nosocomial transmission as the source of infection in patients or health-care workers. Funding: EU Horizon 2020 (RECoVer, VEO, and the European Joint Programme One Health METASTAVA), and the National Institute of Allergy and Infectious Diseases, National Institutes of Health. (Copyright © 2020 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 license. Published by Elsevier Ltd.. All rights reserved.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu